Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05216042 · ClinicalTrials.gov registry record · NA
GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
A NA study of Obesity and Cardiovascular Diseases, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05216042: Recruiting NA study of Obesity and Cardiovascular Diseases, sponsored by University of Alabama at Birmingham.
NCT05216042 is a NA study of Obesity and Cardiovascular Diseases that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 200 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05216042, a NA study of Obesity and Cardiovascular Diseases, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \~30% lower levels of NP and are at a greater risk of developing cardiovascular (CV) events as compared to lean and White counterparts. Some people have common genetic variations that cause them to have \~20% lower NP levels. Similar to other low NP populations, these individuals with low NP genotype (i.e., carrying a common genetic variation called rs5068) are at a greater risk of developing cardiometabolic diseases. By understanding the NP response following the exercise challenge and the glucose challenge in individuals with genetically lower NP levels will help us understand how to improve cardiometabolic health in them.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Study diet
- OTHER Exercise capacity VO2 max determination
- OTHER Exercise Challenge
- OTHER Glucose Challenge
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2027-04-30 |
| Phase | NA |
What NCT05216042 shows while recruiting
NCT05216042 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (76% lower).
The record links to 7 conditions, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Study diet is the first listed.
NCT05216042 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05216042 about?
NCT05216042 is a clinical study titled "GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study". Natriuretic Peptides (NP) are hormones produced by the heart, and they have a wide range of favorable metabolic benefits. Lower levels of these hormones are associated with an increased likelihood of the development of diabetes and poor cardiometabolic health. Obese and Black individuals have \~30% ...
What is the current status of trial NCT05216042?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2022-04-01. Estimated completion is 2027-04-30.
What conditions does trial NCT05216042 study?
This clinical trial studies the following conditions: Obesity, Cardiovascular Diseases, Exercise, Energy Expenditure, Glucose Metabolism.
What interventions are being tested in trial NCT05216042?
The interventions under investigation include: Study diet (DIETARY_SUPPLEMENT), Exercise capacity VO2 max determination (OTHER), Exercise Challenge (OTHER), Glucose Challenge (OTHER).
Who is sponsoring clinical trial NCT05216042?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05216042 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05216042's enrollment target sits among peer trials
200 315th of 1053 higher than 732 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
SMARTer Weight Loss Management
RECRUITING · NA
-
HealthyTogether: RCT of a Dyadic Weight Management Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI